1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.
1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology.
复制标题
DOI：
10.1200/jco.1998.16.2.793
复制
发表时间：
1998-02
期刊：
影响因子：
--
通讯作者：
R. Bast;C. Desch;D. Hayes;N. Kemeny;P. Ravdin;M. Somerfield;Thomas J. Smith
中科院分区：
文献类型：
--
作者：
R. Bast;C. Desch;D. Hayes;N. Kemeny;P. Ravdin;M. Somerfield;Thomas J. Smith
目的：主要目的是更新1996年临床实践指南，在预防，筛查，治疗和监测乳腺癌和结直肠癌的肿瘤标志物检测的使用。这些指南旨在用于临床试验以外的患者护理。选择六种肿瘤标志物的结直肠癌和八个乳腺癌被认为是。它们可以推荐或不推荐用于常规或特殊情况。除了癌胚抗原（CEA）和癌抗原（CA）15-3外，CA 27.29也被认为是乳腺癌的循环肿瘤标志物。结果一般来说，确定用于制定临床实践指南的重要健康结果（总生存期、无病生存期、生活质量、毒性较小和成本效益）。证据计算机文献检索从1994年至1997年7月进行。委员会使用了相同的使用、效用和证据等级值。收益、危害和成本使用相同的收益、危害和成本。建议不建议对任何准则进行修改（见案文）。验证由美国临床肿瘤学会（ASCO）卫生服务研究委员会和ASCO董事会进行外部审查。美国临床肿瘤学会（American Society of Clinical Oncology）
OBJECTIVE The primary objective was to update the 1996 clinical practice guidelines for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast and colorectal cancers. These guidelines are intended for use in the care of patients outside of clinical trials. OPTIONS Six tumor markers for colorectal cancer and eight for breast cancer were considered. They could be recommended or not for routine use or for special circumstances. In addition to carcinoembryonic antigen (CEA) and cancer antigen (CA) 15-3, CA 27.29 also was considered in regard to circulatory tumor markers for breast cancer. OUTCOMES In general, the significant health outcomes identified for use in making clinical practice guidelines (overall survival, disease-free survival, quality of life, lesser toxicity, and cost effectiveness) were used. EVIDENCE A computerized literature search from 1994 to July 1997 was performed. VALUES The same values for Use, Utility, and Levels of Evidence were used by the Committee. BENEFITS, HARMS, AND COSTS The same benefit, harms, and costs were used. RECOMMENDATION No changes in any guidelines were recommended (see text). VALIDATION External review by the American Society of Clinical Oncology (ASCO) Health Services Research Committee and by ASCO Board of Directors. SPONSOR American Society of Clinical Oncology.